Common Questions

Why target China specifically?

China has designated biotechnology as a strategic national priority. The Chinese government subsidizes its biotech industry, and Chinese companies now supply 28% of Big Pharma's in-licensed drugs. This creates a dependency that undermines US national security and economic competitiveness. The BIOSECURE Act already established precedent for treating Chinese biotech differently.

Doesn't this violate WTO rules?

Potentially challengeable, but defensible. The US can invoke national security exceptions under GATT Article XXI, which the US has used for steel/aluminum tariffs. The BIOSECURE Act—which specifically names Chinese companies—passed without significant WTO challenge. The bigger question is whether the US cares about WTO compliance for national security measures.

Won't China retaliate?

China is already retaliating against US tariffs with 125%+ counter-tariffs. The US-China trade relationship is already adversarial. This policy extracts value from Chinese IP while allowing the drugs to remain on the US market—arguably less provocative than outright bans. Chinese biotechs need US market access more than the US needs any single drug.

Will this raise drug prices?

Minimal impact. Progressive rates (3-15%) apply to manufacturer revenue, not consumer prices. Companies can offset up to 75% by investing in US R&D. Even without offsets, pharma's 20-25% net margins can absorb modest levies. Affected drugs represent <1% of US drug spending. The IRA's much larger price controls haven't caused market withdrawals.

What about patients who need these drugs?

The policy doesn't restrict access. Chinese-licensed drugs remain available—they just have to contribute to US R&D. If anything, this creates incentives for more domestic drug development over time, increasing patient options.

Why progressive rates instead of a flat 10%?

A flat 10% is unfair across drug types. It takes 100% of profit from a 10%-margin generic but only 25% from a high-margin CAR-T therapy. Our progressive structure (3-15% based on revenue) protects smaller drugs while capturing more from blockbusters. Plus, up to 75% can be offset by investing in US R&D and manufacturing. See our detailed rate design analysis.

How would this be enforced?

Through the tax code, like the IRA. Companies report revenue and R&D spending annually. If they don't meet the 10% threshold, they either pay into the Fund or face an excise tax equal to the shortfall. The IRS already has infrastructure for pharmaceutical tax enforcement.

What counts as 'qualified' US R&D?

The bill uses existing IRS definitions from the R&D tax credit (IRC Section 41). Work must be substantially performed in the US by US employees, US contractors, or US academic institutions. Marketing, lobbying, and litigation don't count. Payments to Chinese entities are explicitly excluded.

Could companies just stop licensing from China?

Unlikely. Chinese biotechs have developed 639 first-in-class candidates since 2022—innovation US companies need. Chinese drugs like BRUKINSA generate billions in US revenue. A 10% haircut still leaves 90% of profits. Companies will pay the cost rather than lose access to Chinese innovation.

What about drugs already approved?

The bill applies to all Chinese-licensed drugs generating US revenue, including those already on market. There's a transition period (2 years after enactment) for companies to adjust. The 'covered drug' determination is based on facts at original approval.

Who administers the Fund?

Joint HHS and Commerce administration, with an advisory committee including academics, industry, patient advocates, and national security officials. Funds go to domestic R&D grants, workforce development, and biomanufacturing infrastructure. 5% cap on administrative overhead.

Is this constitutional?

Yes. The IRA's much more aggressive pharmaceutical provisions have survived constitutional challenge. Courts have upheld the government's broad authority over foreign commerce and national security. A 10% revenue-based requirement is a modest economic regulation that would receive deferential rational-basis review.

Which drugs would be affected?

Currently approved: BRUKINSA (BeiGene, $2B), CARVYKTI (Legend/J&J, ~$1B), TEVIMBRA (BeiGene), Loqtorzi (Junshi), Fruzaqla (Hutchmed). Pipeline: BL-B01D1 (BMS/Biokin, $8.4B deal), ivonescimab (Summit/Akeso), LM-299 (Merck/LaNova). Combined, potentially $20-30B in US revenue by 2030.

How much would this generate?

With progressive rates: ~$300M in 2025, scaling to $2.1B by 2030 (before credits). After reshoring credits are claimed, net revenue is ~$1.3B by 2030. But the credits aren't lost money—they're triggering $800M+ in annual US R&D investment. Total value creation (fund + triggered investment) exceeds the flat 10% approach.